BioSpace News Archive

According to the report, the global equine diagnostic services market was valued at ~US$ 168 Mn in 2019.

Laboratory information management systems have evolved continuously on the back of evolving and changing needs of lab infrastructures for clinical and research ends.

According to the report, the global needle biopsy market was valued at ~US$ 630 Mn in 2019. It is projected to expand at a moderate CAGR during the forecast period.

According to the report, the global pharmaceutical testing and analytical services market was valued at US$ 3.5 Bn in 2019. It is projected to expand at a CAGR of ~11% from 2020 to 2030.

Transparency Market Research has published a new report titled, ‘Surgical Drainage Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.

The Terasaki Institute for Biomedical Innovation, a research institute at the frontier of personalized and precision medicine, and HTL Biotechnology, the world leader in using hyaluronic acid and other biopolymers for biotechnology solutions, announce their Memorandum of Understanding to explore the creation of a joint research program.

On 6th May 2021, the Annual General Meeting was held in Immunovia AB, 556730-4299. Due to the extraordinary situation following the COVID-19-pandemic, the AGM was carried out through advance voting pursuant to temporary legislation.

Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced that early clinical data from a Phase 1 dose-escalation study of Tessa’s TT11X allogeneic CD30-CAR Epstein Barr Virus Specific T-cell (EBVST) therapy in patients with CD30-positive lymphoma will be featured in a podium presentation

Waterdrop Inc. (“Waterdrop” or the “Company”), a leading technology platform dedicated to insurance and healthcare services with a positive social impact, today announced the pricing of its initial public offering (“IPO”) of 30,000,000 American depositary shares (“ADSs”), each representing 10 Class A ordinary shares of the Company, at a price of US$12.0 per ADS.

Perosphere Technologies Inc. today announced CE (Conformité Européene)-IVD Marking of its Point-of-Care (PoC) Coagulometer System.